Trial Profile
A Canadian Randomized Controlled Trial of DMARD Withdrawal in RA Patients Achieving Therapeutic Response With Cimzia + DMARD Combination Treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Oct 2019
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary) ; Disease-modifying antirheumatics
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 18 Oct 2019 Status changed from active, no longer recruiting to completed according to results published in the Rheumatology.
- 18 Oct 2019 Primary endpoint has not been met. (The percentage of patients achieving DAS283.2 or maintaining a change in DAS from baseline of 1.2 at 18 months.)
- 18 Oct 2019 Results published in the Rheumatology